Logo

American Heart Association

  7
  0


Final ID: LB19

THE INTRACEREBRAL HEMORRHAGE ACUTELY DECREASING ARTERIAL PRESSURE TRIAL II FINAL RESULTS

Abstract Body: Background and Aims

Diffusion-Weighted Imaging (DWI) lesions have been demonstrated in sub-acute Intracerebral Hemorrhage (ICH) patients, suggesting ischemic injury which may be related to Blood Pressure (BP) reduction. We conducted a randomized trial to test the hypothesis that acute BP lowering is associated with DWI lesions after ICH.

Methods
ICH ADAPT II (NCT02281838) was a multicentre randomized open-label, blinded-endpoint trial. ICH patients were randomized to a systolic BP (SBP) target of <140mmHg or <180mmHg within 6 hours of onset. The primary outcome was DWI lesion incidence assessed on 48h MRI.

Results
A total of 162 ICH patients were randomized at a median of 3.17 (IQR 2.27) hours after onset. DWI was obtained at 51.6 (27.0) hours in 79 patients (age 72 (21) years with ICH volume of 11.2 (range 0.5-122.2) ml. Mean baseline SBP was 183±22 mmHg in the <140 and 181±28 mmHg in the <180 target groups. One hour after randomization, mean SBP was 144±22 mmHg in the<140 group and 167±23 mmHg in the <180 group. (adjusted mean difference 12.7 [2.5, 22.8] mmHg, p=0.0146). Mean SBP remained lower over the 48-hour period after randomization in the <140 group (adjusted mean difference for period 12.6 [11.2, 13.9] mmHg, p<0.0001).

DWI lesions were detected in 12/42 (28.6%) patients in the <140mmHg group and 14/37 (37.8%) in the <180mmHg group (OR=0.65 [0.10, 4.21], p=0.237). Multivariate logistic regression indicated that ischemic lesions were predicted by baseline ICH volume (beta=0.0487 [0.018,0.080], p=0.002), but not SBP treatment. The median number of DWI lesions (1(0) vs 1(1.75), p=0.385) and total DWI lesion volume (0.1 (0.1) ml vs 0.34 (0.76) ml, p=0.198) was not different in the <140mmHg and <180mmHg groups. One patient with a 29.5 ml baseline ICH volume (35 ml at 24 hours) in the <140mmHg group developed extensive bilateral internal borderzone DWI changes (volume=41.3 ml) following SBP reduction from 223 mmHg to 187 mmHg at 1 hour.

Conclusions
We found no evidence that low volume DWI lesions in ICH patients are precipitated or aggravated by antihypertensive therapy in acute ICH. Further MRI studies in acute ICH are required to determine predicators of less common large volume ischemic lesions.
  • Butcher, Ken  ( UNIVERSITY of New South Wales , Randwick , New South Wales , Australia )
  • Wilman, Alan  ( University of Alberta , Edmonton , Alberta , Canada )
  • Sharma, Vijay  ( National University of Singapore , Singapore , Singapore )
  • Tsivgoulis, Georgios  ( Neurodiagnostics PC , Athens , Greece )
  • Krogias, Christos  ( ST JOSEF-HOSPITAL RUHR UNIVERSITY , Bochum , Germany )
  • Dowlatshahi, Dar  ( UNIV OTTAWA , Ottawa , Ontario , Canada )
  • Shoamanesh, Ashkan  ( MCMASTER UNIVERSITY , Hamilton , Ontario , Canada )
  • Buck, Brian  ( University of Alberta , Edmonton , Alberta , Canada )
  • Gioia, Laura  ( CHUM-UNIVERSITY OF MONTREAL , Montreal , Quebec , Canada )
  • Kate, Mahesh  ( University of Alberta , Edmonton , Alberta , Canada )
  • Klahr, Ana  ( University of Alberta , Edmonton , Alberta , Canada )
  • Sivasubramaniam, Ashwin  ( UNIVERSITY of New South Wales , Randwick , New South Wales , Australia )
  • Shuaib, Ashfaq  ( University of Alberta , Edmonton , Alberta , Canada )
  • Author Disclosures:
    Ken Butcher: DO NOT have relevant financial relationships | Alan Wilman: DO NOT have relevant financial relationships | Vijay Sharma: DO NOT have relevant financial relationships | Georgios Tsivgoulis: DO NOT have relevant financial relationships | Christos Krogias: DO NOT have relevant financial relationships | Dar Dowlatshahi: DO NOT have relevant financial relationships | Ashkan Shoamanesh: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Daiichi Sankyo:Active (exists now) ; Consultant:Bioxides:Past (completed) ; Speaker:Bayer AG:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Speaker:AstraZeneca:Active (exists now) ; Consultant:Bayer AG:Active (exists now) ; Consultant:Daiichi Sankyo:Active (exists now) | Brian Buck: DO NOT have relevant financial relationships | Laura Gioia: DO have relevant financial relationships ; Speaker:Astrazeneca:Active (exists now) ; Advisor:Servier:Past (completed) ; Advisor:Astrazeneca:Active (exists now) | Mahesh Kate: DO NOT have relevant financial relationships | Ana Klahr: DO NOT have relevant financial relationships | Ashwin Sivasubramaniam: No Answer | Ashfaq Shuaib: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Thursday Main Event

Thursday, 02/06/2025 , 11:00AM - 12:30PM

ISC Invited Symposium

More abstracts on this topic:
A major effect of aprocitentan on albuminuria in patients with resistant hypertension

Weber Michael, Bakris George, Flack John, Gimona Alberto, Narkiewicz Krzysztof, Sassi-sayadi Mouna, Wang Jiguang, Schlaich Markus

A closed-loop system based on piezoelectric thin-film sensors and photothermal nanomaterials enables precise renal denervation for the treatment of hypertension

Liu Chengzhe, Zhou Liping, Yu Lilei

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)